Accessibility Menu
Verona Pharma Plc logo

Verona Pharma Plc

(NASDAQ) VRNA

This security has been delisted. This page is retained for historical reference.

Verona Pharma Plc last closing stock price
MetricPriceDate
Last closeUSD 106.912025-10-06
Verona Pharma Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.28%USD 106.612025-09-29
1 month+0.56%USD 106.312025-09-05
3 month+23.08%USD 86.862025-07-08
Year to date+130.21%USD 46.442024-12-31
1 year+233.99%USD 32.012024-10-04
3 year+955.38%USD 10.132022-10-07
5 year+1,641.21%USD 6.142020-10-07
Since inception+691.93%USD 13.502017-04-27

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

VRNA Financials

Key Financial Metrics (TTM)

Gross Margin

95.45%

Operating Margin

1.27%

Net Income Margin

-2.94%

Return on Equity

-1.56%

Return on Capital

-37.74%

Return on Assets

-0.69%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$159.52M

Operating Income

-$43.36M

EBITDA

-$40.86M

Operating Cash Flow

-$72.48M

Capital Expenditure

-$1.03M

Free Cash Flow

-$73.56M

Cash & ST Invst.

$438.02M

Total Debt

$244.37M

Verona Pharma Plc Performance Analysis

Verona Pharma Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 39,995,234N/A
20222022-12-31USD 457,717-98.9%
20232023-12-31USD 0N/A
20242024-12-31USD 42,296,791N/A
Verona Pharma Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32024-09-30N/A
Q42024-12-31596.0%
Q12025-03-31101.6%
Q22025-06-3027.3%
Verona Pharma Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -0.94N/A
20222022-12-31USD -1.0410.5%
20232023-12-31USD -0.69-33.7%
20242024-12-31USD -2.13209.0%
Verona Pharma Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32024-09-3044.3%
Q42024-12-3110.3%
Q12025-03-3157.2%
Q22025-06-30166.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

$75.14M

N/A

Gross Profit

$71.68M

N/A

Gross Margin

95.39%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

209

N/A

Net Income

$8.69M

+115.5%

EBITDA

$9.91M

+118.6%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

$438.02M

+8.3%

Total Debt

$244.37M

+100.0%

Accounts Receivable

$86.92M

+2259.4%

Inventory

$8.61M

N/A

Long Term Debt

$243.36M

+100.9%

Short Term Debt

$1.01M

-1.6%

Return on Assets

-0.69%

N/A

Return on Invested Capital

0.33%

N/A

Free Cash Flow

$30.56M

+282.1%

Operating Cash Flow

$30.56M

+282.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SGENSeagen Inc.
$228.74-0.07%
BDXBecton, Dickinson and Company
$159.93+3.26%
ALPNAlpine Immune Sciences, Inc.
$64.97+0.02%
IMGNImmunoGen, Inc.
$31.24+0.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$15.60-0.00%
ATAIAtaiBeckley
$7.15+0.33%
ONDSOndas
$6.65-0.06%
INTCIntel
$96.98-0.06%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.